PPX, Temozolomide, and Concurrent Radiation for Newly Diagnosed Brain Tumors
The purpose of this study is to determine the antitumor activity of PPX in combination with temozolomide and radiation for patients with newly diagnosed brain tumors.
Brain Tumor
DRUG: PPX +TMZ+XRT
Number of Patients Assessed for Toxicity According to CTC Version 3.0, Throughout the entire study until patient is removed from study an average of 6 weeks
To evaluate the safety/tolerability and potential antitumor activity of PPX in combination with temozolomide and radiation for patients with newly diagnosed brain tumors.